Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1617srh

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

```
  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:59:39 ON 21 JUL 2003

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:59:57 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 JUL 2003  HIGHEST RN 551897-78-0
DICTIONARY FILE UPDATES:  20 JUL 2003  HIGHEST RN 551897-78-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading aryl nitrone for neuropathic pain.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```




```
G1 O,S


Structure attributes must be viewed using STN Express query preparation.
```

```
=> s l1
SAMPLE SEARCH INITIATED 12:00:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      0 TO ITERATE

100.0% PROCESSED       0 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:00:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     13 TO ITERATE

100.0% PROCESSED      13 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

L3             0 SEA SSS FUL L1

=> fil marpat
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     148.15     148.36

FILE 'MARPAT' ENTERED AT 12:00:22 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 15-VOL 139 ISS03)(200300718ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6580000 17 JUN 2003
DE   20300703 26 JUN 2003
EP    1321471 25 JUN 2003
JP 2003173782 20 JUN 2003
WO 2003051918 26 JUN 2003

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1
SAMPLE SEARCH INITIATED 12:00:25 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -    223 TO ITERATE

100.0% PROCESSED     223 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3572 TO     5348
PROJECTED ANSWERS:               1 TO       80

L4             1 SEA SSS SAM L1

=> d
```

```
L4   ANSWER 1 OF 1  MARPAT  COPYRIGHT 2003 ACS on STN
AN   127:262678  MARPAT
TI   Preparation of novel indoles and benzothiazoles for cloned human alpha 2
     receptors
IN   Jeon, Yoon T.; Gluchowski, Charles
PA   Synaptic Pharmaceutical Corp., USA
SO   PCT Int. Appl., 73 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
PI   WO 9731636         A1   19970904      WO 1997-US3173   19970228
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN,
             YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
             ML, MR, NE, SN, TD, TG
     US 5677321          A    19971014      US 1996-608598   19960229
     CA 2246813          AA   19970904      CA 1997-2246813  19970228
     AU 9720604          A1   19970916      AU 1997-20604    19970228
     AU 704439           B2   19990422
     EP 900080           A1   19990310      EP 1997-908782   19970228
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2000506144       T2   20000523      JP 1997-531156   19970228
     US 5948804          A    19990907      US 1997-926316   19970905
     US 6040451          A    20000321      US 1999-345470   19990630
     US 6159998          A    20001212      US 2000-492505   20000127
     US 6303643          B1   20011016      US 2000-690620   20001017
     US 2002049239       A1   20020425      US 2001-965944   20010928
     US 6498177          B2   20021224
     US 2003105147       A1   20030605      US 2002-278608   20021022
PRAI US 1996-608598    19960229
     WO 1997-US3173    19970228
     US 1997-926316    19970905
     US 1999-345470    19990630
     US 2000-492505    20000127
     US 2000-690620    20001017
     US 2001-965944    20010928


=> s l1 full
FULL SEARCH INITIATED 12:00:51 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   4776 TO ITERATE

 97.2% PROCESSED    4642 ITERATIONS                          22 ANSWERS

100.0% PROCESSED    4776 ITERATIONS                          23 ANSWERS
SEARCH TIME: 00.00.28

L5           23 SEA SSS FUL L1

=> d tot

L5   ANSWER 1 OF 23  MARPAT  COPYRIGHT 2003 ACS on STN
AN   138:338145  MARPAT
TI   Preparation of 5-[4-(6-phenoxy-1-methyl-1H-benzimidazo-2-
     ylmethoxy)benzyl]thiazolidine-2,4-dione derivatives as antitumor agents
IN   Shibata, Tomoyuki; Kurakata, Shinichi; Shimazaki, Naomi
PA   Sankyo Company, Limited, Japan
```

SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003032988	A1	20030424	WO 2002-JP10707	20021016
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003192592	A2	20030709	JP 2002-299928	20021015

PRAI JP 2001-319631 20011017
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 138:255256 MARPAT
TI Preparation of triazines as inhibitors of glycated protein-produced induction of the signaling-assocd. inflammatory response in endothelial cells
IN Timmer, Richard T.; Alexander, Christopher W.; Pillarisetti, Sivaram; Saxena, Uday; Campbell, Karen A.
PA Reddy US Therapeutics, Inc., USA
SO PCT Int. Appl., 396 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003024926	A2	20030327	WO 2002-US30177	20020923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-324147P 20010921

L5 ANSWER 3 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 138:238180 MARPAT
TI Preparation of pyrazolopyridines for treatment of herpes infections
IN Johns, Brian A.; Gudmundsson, Kristjan
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2003022845 A1 20030320 WO 2002-US27251 20020827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-318203P 20010907
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 138:187778 MARPAT
TI Prepn. of diazobenzoanthracenes and related compounds as poly(ADP-ribose) polymerase (PARP) inhibitors
IN Xu, Weizheng; Ferraris, Dana V.; Li, Jia-He; Kalish, Vincent J.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003014121	A1	20030220	WO 2002-US24857	20020806

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-310252P 20010807
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 138:149044 MARPAT
TI Synergistic herbicidal compositions
IN Schaetzer, Juergen; Wenger, Jean; Hall, Roger Graham; Nebel, Kurt; Hole, Stephen
PA Syngenta Participations A.-G., Switz.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003009686	A1	20030206	WO 2002-EP8203	20020723

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI CH 2001-1377 20010724
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 135:152622 MARPAT
TI Preparation of herbicidal substituted 1-phenyl-3-phenoxypropynes
IN Craig, Gerald Wayne; Eberle, Martin; Zeller, Martin; Bondy, Steven Scott; Comer, Daniel Dennis; Cheng, Soan; Penzotti, Julie Elizabeth; Grootenhuis, Peter Diederik Jan; Ehrler, Juerg
PA Syngenta Participations A.-G., Switz.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055066	A2	20010802	WO 2001-EP718	20010123
	WO 2001055066	A3	20020131		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1250314	A2	20021023	EP 2001-901194	20010123
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001007770	A	20030429	BR 2001-7770	20010123
PRAI	GB 2000-1702	20000125			
	GB 2000-20686	20000822			
	WO 2001-EP718	20010123			

L5 ANSWER 7 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 135:53459 MARPAT
TI Color photographic silver halide material
IN Hagemann, Jorg; Haller, Jan; Helling, Gunter
PA Agfa-Gevaert N.V., Belg.
SO Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1109062	A1	20010620	EP 2000-204017	20001115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001183784	A2	20010706	JP 2000-376077	20001211
	US 2001016304	A1	20010823	US 2000-734634	20001212
	US 6383728	B2	20020507		
	US 6436623	B1	20020820	US 2001-16311	20011031
PRAI	DE 1999-19960899	19991217			
	US 2000-734634	20001212			

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 134:306619 MARPAT
TI Synergistic herbicides containing hydroxyphenylpyruvate dioxygenase inhibitors
IN Bieringer, Hermann; Van Almsick, Andreas; Hacker, Erwin; Willms, Lothar
PA Aventis Cropscience Gmbh, Germany
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028341	A2	20010426	WO 2000-EP10369	20001020
	WO 2001028341	A3	20020502		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19950943	A1	20010517	DE 1999-19950943	19991022
	BR 2000014915	A	20020611	BR 2000-14915	20001020
	EP 1233673	A2	20020828	EP 2000-972832	20001020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511475	T2	20030325	JP 2001-530945	20001020
	BG 106600	A	20021229	BG 2002-106600	20020410
PRAI	DE 1999-19950943	19991022			
	WO 2000-EP10369	20001020			

L5 ANSWER 9 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 134:131317 MARPAT
TI Preparation of 2-phenylaminobenzamides and analogs as MEK inhibitors for the treatment of chronic pain
IN Dixon, Alistair; Lee, Kevin; Pinnock, Robert Denham
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005392	A2	20010125	WO 2000-US18347	20000705
	WO 2001005392	A3	20010719		
	W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1202726	A2	20020508	EP 2000-943383	20000705
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI	US 1999-144292P	19990716			
	WO 2000-US18347	20000705			

L5 ANSWER 10 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 132:89504 MARPAT
TI Manufacture of amide-containing rodent repellent

IN Liu, Dongxue; Wei, Feng; Wang, Baorong; Wu, Yuchun; Fang, Hui
PA Shenyang Chemical Inst., Ministry of Chemical Industry, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 36 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1172582	A	19980211	CN 1997-115109	19970721
	CN 1067215	B	20010620		
PRAI	CN 1997-115109		19970721		

L5 ANSWER 11 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 130:168370 MARPAT
TI Preparation of hydantoin derivatives as farnesyl transferase inhibitors
IN Lee, Jin Ho; Koh, Jong Sung; Kim, Jong Hyun; Lee, Hyun Il; Jung, Won Hee; Ro, Seong Gu; Shin, You Seung; Kim, Sang Woong; Park, Ki Won; Kwak, Tae Hwan; Moon, Kyung Duk; Chung, Hyun Ho
PA LG Chemical Ltd., S. Korea
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9905117	A1	19990204	WO 1998-KR225	19980724
	W: AU, BR, CN, JP, MX, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9806623	A	19990126	ZA 1998-6623	19980724
	AU 9884647	A1	19990216	AU 1998-84647	19980724
	AU 729341	B2	20010201		
	EP 1000036	A1	20000517	EP 1998-935376	19980724
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001510829	T2	20010807	JP 2000-504116	19980724
	US 6384061	B1	20020507	US 2000-463551	20000330
PRAI	KR 1997-35333		19970726		
	WO 1998-KR225		19980724		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 129:230539 MARPAT
TI Preparation of herbicidal 2-cyano-3-phenyl-1,3-diones
IN Cain, Paul Alfred; Cramp, Susan Mary; Lambert, Claude; Wallis, Derek Ian; Yarwood, Thomas David; Little, Gillian Mary; Morris, John; Musil, Tibor; Pettit, Simon Neil; Smith, Philip Henry Gaunt; et al.
PA Rhone-Poulenc Agriculture Ltd., UK
SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 304,482, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5804532	A	19980908	US 1995-458300	19950602
	ZA 9403428	A	19950209	ZA 1994-3428	19940518
PRAI	GB 1991-1659		19910125		
	GB 1991-1660		19910125		
	US 1992-825258		19920124		
	US 1992-825274		19920124		
	GB 1993-10203		19930518		

GB 1993-10222 19930518
US 1993-92058 19930716
US 1993-94881 19930722
US 1994-304482 19940912
US 1994-309646 19940921
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 127:262678 MARPAT
TI Preparation of novel indoles and benzothiazoles for cloned human alpha 2 receptors
IN Jeon, Yoon T.; Gluchowski, Charles
PA Synaptic Pharmaceutical Corp., USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9731636	A1	19970904	WO 1997-US3173	19970228
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5677321	A	19971014	US 1996-608598	19960229
CA 2246813	AA	19970904	CA 1997-2246813	19970228
AU 9720604	A1	19970916	AU 1997-20604	19970228
AU 704439	B2	19990422		
EP 900080	A1	19990310	EP 1997-908782	19970228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000506144	T2	20000523	JP 1997-531156	19970228
US 5948804	A	19990907	US 1997-926316	19970905
US 6040451	A	20000321	US 1999-345470	19990630
US 6159998	A	20001212	US 2000-492505	20000127
US 6303643	B1	20011016	US 2000-690620	20001017
US 2002049239	A1	20020425	US 2001-965944	20010928
US 6498177	B2	20021224		
US 2003105147	A1	20030605	US 2002-278608	20021022

PRAI US 1996-608598 19960229
WO 1997-US3173 19970228
US 1997-926316 19970905
US 1999-345470 19990630
US 2000-492505 20000127
US 2000-690620 20001017
US 2001-965944 20010928

L5 ANSWER 14 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 125:107784 MARPAT
TI Pesticidal substituted diketonitriles
IN Cain, Paul A.; Chou, David T.; Da Silva, Themistocles D. J.; Gant, Daniel B.; Herman, Nancy D.
PA Rhone-Poulenc Inc., USA
SO Statutory Invent. Regist., 12 pp.
CODEN: SRXXEV
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 1552	H1	19960604	US 1994-259088	19940613
PRAI	US 1994-259088	19940613			

L5 ANSWER 15 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 125:33683 MARPAT
TI Aromatic amino ethers as pain relieving agents
IN Breault, Gloria Anne; Oldfield, John; Tucker, Howard; Warner, Peter
PA Zeneca Limited, UK
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603380	A1	19960208	WO 1995-GB1728	19950721
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2192088	AA	19960208	CA 1995-2192088	19950721
	AU 9529883	A1	19960222	AU 1995-29883	19950721
	AU 688541	B2	19980312		
	EP 773930	A1	19970521	EP 1995-925943	19950721
	EP 773930	B1	20001011		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1154106	A	19970709	CN 1995-194340	19950721
	CN 1085663	B	20020529		
	BR 9508335	A	19970930	BR 1995-8335	19950721
	HU 76606	A2	19971028	HU 1996-3338	19950721
	JP 10503487	T2	19980331	JP 1995-505573	19950721
	AT 196898	E	20001015	AT 1995-925943	19950721
	ES 2150577	T3	20001201	ES 1995-925943	19950721
	TW 411328	B	20001111	TW 1995-84107606	19950722
	ZA 9506149	A	19960207	ZA 1995-6149	19950724
	FI 9700261	A	19970122	FI 1997-261	19970122
	NO 9700314	A	19970313	NO 1997-314	19970124
	US 5843942	A	19981201	US 1997-776275	19970124
	CN 1286254	A	20010307	CN 2000-104017	20000310
PRAI	GB 1994-14924	19940725			
	GB 1995-1288	19950124			
	WO 1995-GB1728	19950721			

L5 ANSWER 16 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 124:343326 MARPAT
TI Preparation of substituted 4-aminopyrimido[5,4-d]pyrimidine antineoplastic agents
IN Himmelsbach, Frank; Von rueden, Thomas
PA Dr. Karl Thomae Gmbh, Germany
SO Ger. Offen., 39 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4431867	A1	19960314	DE 1994-4431867	19940907
	TW 414798	B	20001211	TW 1995-84109086	19950831
	CA 2199401	AA	19960304	CA 1995-2199401	19950905
	WO 9607657	A1	19960314	WO 1995-EP3482	19950905
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE,				

KG, KP, KR, KZ, LK, LR, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU,
SD, SG, SK, TJ, TM, TT, UA, UG, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG

AU	9535218	A1	19960327	AU 1995-35218	19950905
AU	688972	B2	19980319		
EP	779888	A1	19970625	EP 1995-931988	19950905
EP	779888	B1	19990428		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

CN	1157619	A	19970820	CN 1995-194919	19950905
CN	1047778	B	19991229		
JP	10505078	T2	19980519	JP 1995-509206	19950905
HU	77744	A2	19980728	HU 1998-482	19950905
AT	179420	E	19990515	AT 1995-931988	19950905
ES	2133800	T3	19990916	ES 1995-931988	19950905
JP	3184533	B2	20010709	JP 1996-509206	19950905
ZA	9507464	A	19970306	ZA 1995-7464	19950906
US	5707989	A	19980113	US 1995-524707	19950907
NO	9701038	A	19970506	NO 1997-1038	19970306
BG	62969	B1	20001229	BG 1997-101289	19970306
FI	9700968	A	19970506	FI 1997-968	19970307
HK	1000837	A1	20001103	HK 1997-102471	19971217

PRAI DE 1994-4431867 19940907
DE 1995-19503151 19950201
DE 1995-19521386 19950613
DE 1995-19528672 19950804
WO 1995-EP3482 19950905

L5 ANSWER 17 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 123:340138 MARPAT
TI Preparation of heterocyclic-fused lactams which promote the release of growth hormone
IN Fisher, Michael H.; Mrozik, Helmut; Schoen, William R.; Shih, Thomas L.; Wyvratt, Matthew J.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 9516692	A1	19950622	WO 1994-US14130	19941209

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US	5606054	A	19970225	US 1993-166440	19931214
AU	9513374	A1	19950703	AU 1995-13374	19941209
ZA	9409899	A	19950818	ZA 1994-9899	19941213
US	5789587	A	19980804	US 1996-744296	19961106

PRAI US 1993-166440 19931214
WO 1994-US14130 19941209

L5 ANSWER 18 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 123:313795 MARPAT
TI Preparation of ureidobenzaepinones as growth hormone release stimulants
IN Ok, Hyun O.; Schoen, William R.; Szumiloski, John
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9516675	A1	19950622	WO 1994-US14374	19941209
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9513718	A1	19950703	AU 1995-13718	19941209
PRAI	US 1993-149482	19931213			
	WO 1994-US14374	19941209			

L5 ANSWER 19 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 123:256544 MARPAT
TI Preparation of N-(oxobenzazepinyl)alkanamides as growth hormone release promoters
IN Schoen, William R.; Wyvratt, Matthew J., Jr.; Hodges, Paul J.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503290	A1	19950202	WO 1994-US8228	19940720
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5430144	A	19950704	US 1993-97146	19930726
	CA 2167507	AA	19950202	CA 1994-2167507	19940720
	AU 9474024	A1	19950220	AU 1994-74024	19940720
	AU 683081	B2	19971030		
	EP 711287	A1	19960515	EP 1995-906200	19940720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09502961	T2	19970325	JP 1994-505304	19940720
	ZA 9405462	A	19950303	ZA 1994-5462	19940725
PRAI	US 1993-97146	19930726			
	WO 1994-US8228	19940720			

OS CASREACT 123:256544

L5 ANSWER 20 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 123:228011 MARPAT
TI Preparation of N-(benzazepinonyl)alkanamides as growth hormone release promoters
IN Bochis, Richard J.; Hodges, Paul J.; Schoen, William R.; Wyvratt, Matthew J., Jr.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509633	A1	19950413	WO 1994-US11086	19940930
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,				

MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 5545735	A	19960813	US 1993-132074	19931004
	AU 9479616	A1	19950501	AU 1994-79616	19940930
PRAI	US 1993-132074	19931004			
	WO 1994-US11086	19940930			

L5 ANSWER 21 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 123:111666 MARPAT
TI Preparation of 1-aryl-2-cyano-3-cyclopropylpropane-1,3-diones as herbicides.
IN Cain, Paul Alfred; Lambert, Claude; Cramp, Susan Mary; Little, Gillian Mary; Morris, John; Petit, Simon Neil; Smith, Philip Henry; Musil, Tibor
PA Rhone Poulenc Agriculture Ltd., UK
SO Eur. Pat. Appl., 100 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 625505	A2	19941123	EP 1994-107449	19940513
	EP 625505	A3	19950215		
	EP 625505	B1	19981028		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	EP 811611	A1	19971210	EP 1997-109375	19940513
	EP 811611	B1	20000126		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, PT, IE				
	AT 172718	E	19981115	AT 1994-107449	19940513
	ES 2123682	T3	19990116	ES 1994-107449	19940513
	AT 189212	E	20000215	AT 1997-109375	19940513
	ES 2141559	T3	20000316	ES 1997-109375	19940513
	FI 9402291	A	19941119	FI 1994-2291	19940517
	HU 68202	A2	19950628	HU 1994-1519	19940517
	RO 112858	B1	19980130	RO 1994-806	19940517
	CA 2123859	AA	19941119	CA 1994-2123859	19940518
	AU 9463156	A1	19941124	AU 1994-63156	19940518
	AU 680483	B2	19970731		
	ZA 9403428	A	19950209	ZA 1994-3428	19940518
	JP 07070039	A2	19950314	JP 1994-128244	19940518
	CN 1100261	A	19950322	CN 1994-107584	19940518
	CN 1082790	B	20020417		
	BR 9401097	A	19950502	BR 1994-1097	19940518
PRAI	GB 1993-10222	19930518			
	US 1993-94881	19930722			
	EP 1994-107449	19940513			

L5 ANSWER 22 OF 23 MARPAT COPYRIGHT 2003 ACS on STN
AN 121:300926 MARPAT
TI (Heteroarylmethyl)indazole derivatives
IN Baker, Raymond; Kulagowski, Janusz Jozef; Leeson, Paul David; Smith, Adrian Leonard
PA Merck Sharp and Dohme Ltd., UK
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9421626	A1	19940929	WO 1994-GB503	19940314
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				

```
            BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
     CA 2156839        AA   19940929       CA 1994-2156839  19940314
     AU 9462139        A1   19941011       AU 1994-62139    19940314
     AU 679214         B2   19970626
     EP 701555         A1   19960320       EP 1994-909209   19940314
     EP 701555         B1   19990804
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     JP 08507780       T2   19960820       JP 1994-520765   19940314
     AT 182891         E    19990815       AT 1994-909209   19940314
     ES 2133544        T3   19990916       ES 1994-909209   19940314
     US 5665732        A    19970909       US 1995-530226   19950908
PRAI GB 1993-5641     19930318
     WO 1994-GB503    19940314

L5   ANSWER 23 OF 23  MARPAT  COPYRIGHT 2003 ACS on STN
AN   117:209112  MARPAT
TI   Induction of male sterility  in crop plants with heterologous genes
     expressed from tissue-specific promoters
IN   Hsu, Francis C.; Odell, Joan Tellefsen; Shen, Jennie Bih Jien
PA   du Pont de Nemours, E. I., and Co., USA
SO   PCT Int. Appl., 92 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9204454         A1   19920319       WO 1991-US6234   19910905
         W:  AU, CA, JP, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
     AU 9187237         A1   19920330       AU 1991-87237    19910905
PRAI US 1990-578360    19900906
     WO 1991-US6234    19910905


=> fil capl
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              129.59     277.95

FILE 'CAPLUS' ENTERED AT 12:04:06 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 21 Jul 2003  VOL 139 ISS 4
FILE LAST UPDATED: 20 Jul 2003  (20030720/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s waterbury, l?/au
L6          44 WATERBURY, L?/AU
```

```
=> s wood, paul/au
L7          12 WOOD, PAUL/AU

=> s l6 and l7
L8           0 L6 AND L7

=> s khan, m?/au
L9        5776 KHAN, M?/AU

=> s l6 and l9
L10          0 L6 AND L9

=> s wo200265993/pn.b
L11          1 WO200265993/PN.B
               (WO2002065993/PN.B)

=> d

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2002:657919  CAPLUS
DN   137:195593
TI   Methods for the treatment of neuropathic pain by aryl nitrone compounds
IN   Waterbury, David; Wood, Paul L.; Khan, M. Amin; Upasani, Ravindra B.
PA   Centaur Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 82 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2002065993      A2    20020829       WO 2002-US758    20020108
     WO 2002065993      A3    20021107
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002165274      A1    20021107       US 2002-43659    20020108
PRAI US 2001-260469P    P     20010108
OS   MARPAT 137:195593


=> sel rn
E1 THROUGH E60 ASSIGNED

=> fil reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               10.07     288.02

FILE 'REGISTRY' ENTERED AT 12:06:58 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

STRUCTURE FILE UPDATES: 20 JUL 2003 HIGHEST RN 551897-78-0
DICTIONARY FILE UPDATES: 20 JUL 2003 HIGHEST RN 551897-78-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s e1-60

1 107-30-2/BI
(107-30-2/RN)
1 108-24-7/BI
(108-24-7/RN)
1 110-78-1/BI
(110-78-1/RN)
1 111-36-4/BI
(111-36-4/RN)
1 1122-60-7/BI
(1122-60-7/RN)
1 124956-04-3/BI
(124956-04-3/RN)
1 151166-75-5/BI
(151166-75-5/RN)
1 1620-98-0/BI
(1620-98-0/RN)
1 165047-84-7/BI
(165047-84-7/RN)
1 16649-50-6/BI
(16649-50-6/RN)
1 198695-58-8/BI
(198695-58-8/RN)
1 2211-64-5/BI
(2211-64-5/RN)
1 243457-35-4/BI
(243457-35-4/RN)
1 25100-12-3/BI
(25100-12-3/RN)
1 251086-09-6/BI
(251086-09-6/RN)
1 273396-82-0/BI
(273396-82-0/RN)
1 273396-84-2/BI
(273396-84-2/RN)
1 273396-85-3/BI
(273396-85-3/RN)
1 273396-86-4/BI
(273396-86-4/RN)
1 273396-87-5/BI
(273396-87-5/RN)
1 273396-88-6/BI
(273396-88-6/RN)
1 273396-89-7/BI
(273396-89-7/RN)
1 273396-90-0/BI
(273396-90-0/RN)
1 273396-91-1/BI
(273396-91-1/RN)
1 273396-92-2/BI

(273396-92-2/RN)
1 273396-93-3/BI
(273396-93-3/RN)
1 273396-94-4/BI
(273396-94-4/RN)
1 273396-95-5/BI
(273396-95-5/RN)
1 273396-96-6/BI
(273396-96-6/RN)
1 273396-99-9/BI
(273396-99-9/RN)
1 273397-00-5/BI
(273397-00-5/RN)
1 273397-01-6/BI
(273397-01-6/RN)
1 273397-02-7/BI
(273397-02-7/RN)
1 273397-03-8/BI
(273397-03-8/RN)
1 29211-05-0/BI
(29211-05-0/RN)
1 2949-22-6/BI
(2949-22-6/RN)
1 3970-21-6/BI
(3970-21-6/RN)
1 452283-78-2/BI
(452283-78-2/RN)
1 452283-79-3/BI
(452283-79-3/RN)
1 452283-80-6/BI
(452283-80-6/RN)
1 452283-81-7/BI
(452283-81-7/RN)
1 452283-82-8/BI
(452283-82-8/RN)
1 452283-83-9/BI
(452283-83-9/RN)
1 452283-84-0/BI
(452283-84-0/RN)
1 452283-85-1/BI
(452283-85-1/RN)
1 452283-86-2/BI
(452283-86-2/RN)
1 452283-87-3/BI
(452283-87-3/RN)
1 452283-88-4/BI
(452283-88-4/RN)
1 452283-89-5/BI
(452283-89-5/RN)
1 452283-90-8/BI
(452283-90-8/RN)
1 452283-91-9/BI
(452283-91-9/RN)
1 452283-92-0/BI
(452283-92-0/RN)
1 452283-93-1/BI
(452283-93-1/RN)
1 452283-94-2/BI
(452283-94-2/RN)
1 452283-95-3/BI
(452283-95-3/RN)
1 5080-22-8/BI
(5080-22-8/RN)
1 5100-34-5/BI
(5100-34-5/RN)

1 87133-21-9/BI
(87133-21-9/RN)
1 93933-61-0/BI
(93933-61-0/RN)
1 97-72-3/BI
(97-72-3/RN)

L12 60 (107-30-2/BI OR 108-24-7/BI OR 110-78-1/BI OR 111-36-4/BI OR 1122-60-7/BI OR 124956-04-3/BI OR 151166-75-5/BI OR 1620-98-0/BI OR 165047-84-7/BI OR 16649-50-6/BI OR 198695-58-8/BI OR 2211-64-5/BI OR 243457-35-4/BI OR 25100-12-3/BI OR 251086-09-6/BI OR 273396-82-0/BI OR 273396-84-2/BI OR 273396-85-3/BI OR 273396-86-4/BI OR 273396-87-5/BI OR 273396-88-6/BI OR 273396-89-7/BI OR 273396-90-0/BI OR 273396-91-1/BI OR 273396-92-2/BI OR 273396-93-3/BI OR 273396-94-4/BI OR 273396-95-5/BI OR 273396-96-6/BI OR 273396-99-9/BI OR 273397-00-5/BI OR 273397-01-6/BI OR 273397-02-7/BI OR 273397-03-8/BI OR 29211-05-0/BI OR 2949-22-6/BI OR 3970-21-6/BI OR 452283-78-2/BI OR 452283-79-3/BI OR 452283-80-6/BI OR 452283-81-7/BI OR 452283-82-8/BI OR 452283-83-9/BI OR 452283-84-0/BI OR 452283-85-1/BI OR 452283-86-2/BI OR 452283-87-3/BI OR 452283-88-4/BI OR 452283-89-5/BI OR 452283-90-8/BI OR 452283-91-9/BI OR 452283-92-0/BI OR 452283-93-1/BI OR 452283-94-2/BI OR 452283-95-3/BI OR 5080-22-8/BI OR 5100-34

=> d tot

L12 ANSWER 1 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-95-3** REGISTRY
CN Acetic acid, [2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H37 N O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 2 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-94-2** REGISTRY
CN 2-Propanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-ethoxyphenyl]methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H35 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 3 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-93-1** REGISTRY
CN Benzenemethanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H33 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 4 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-92-0** REGISTRY
CN 2-Furanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]tetrahydro-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H33 N O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 5 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-91-9** REGISTRY
CN Cyclohexanemethanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H39 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 6 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-90-8** REGISTRY
CN Pentanoic acid, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H30 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 7 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-89-5** REGISTRY
CN Butanoic acid, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H28 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 8 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-88-4** REGISTRY
CN Propanoic acid, 2-methyl-, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H28 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 9 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-87-3** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[oxido(1,1,3,3-tetramethylbutyl)imino]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H41 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 10 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-86-2** REGISTRY
CN 2-Propanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-methoxyphenyl]methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H33 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 11 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-85-1** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[oxido(phenylmethyl)imino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H29 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 12 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-84-0** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1-methylethyl)oxidoimino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H29 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 13 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-83-9** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylpropyl)oxidoimino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H33 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 14 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-82-8** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(2-hydroxy-1,1-dimethylethyl)oxidoimino]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H31 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 15 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-81-7** REGISTRY
CN Pentanoic acid, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H39 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 16 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-80-6** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1-methylethyl)oxidoimino]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H31 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 17 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-79-3** REGISTRY
CN Butanoic acid, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H37 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 18 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **452283-78-2** REGISTRY
CN Propanoic acid, 2-methyl-, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H37 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1947 TO DATE)
1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 19 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273397-03-8** REGISTRY
CN Glycine, N-[[2,6-bis(1,1-dimethylethyl)-4-formylphenoxy]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H29 N O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)

2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 20 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273397-02-7** REGISTRY
CN .beta.-Alanine, N-[[2,6-bis(1,1-dimethylethyl)-4-formylphenoxy]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H31 N O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 21 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273397-01-6** REGISTRY
CN Carbamic acid, butyl-, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H31 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 22 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273397-00-5** REGISTRY
CN Carbamic acid, propyl-, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H29 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 23 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-99-9** REGISTRY
CN Carbamic acid, ethyl-, 2,6-bis(1,1-dimethylethyl)-4-formylphenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H27 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 24 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-96-6** REGISTRY
CN Methanethiol, [3-[[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]oxidoamino]propoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H35 N O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 25 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-95-5** REGISTRY
CN Methanethiol, [3-[[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]oxidoamino]-1-methylpropoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H37 N O4 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 26 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-94-4** REGISTRY
CN 2-Propanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-[(2-methoxyethoxy)methoxy]phenyl]methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H39 N O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 27 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-93-3** REGISTRY
CN 2-Propanamine, N-[[3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)phenyl]methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H35 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 28 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-92-2** REGISTRY
CN Glycine, N-[[2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenoxy]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H38 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 29 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-91-1** REGISTRY
CN .beta.-Alanine, N-[[2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenoxy]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H40 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 30 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-90-0** REGISTRY
CN Carbamic acid, butyl-, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H40 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 31 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-89-7** REGISTRY
CN Carbamic acid, propyl-, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H38 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 32 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-88-6** REGISTRY
CN Carbamic acid, ethyl-, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]phenyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H36 N2 O3
SR CA

LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 33 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-87-5** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[oxido[(3,4,5-trimethoxyphenyl)methyl]imino]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H37 N O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 34 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-86-4** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[(methyloxidoimino)methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H27 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 35 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-85-3** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]-, propanoate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H35 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 36 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-84-2** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[oxido[[4-(trifluoromethyl)phenyl]methyl]imino]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H30 F3 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 37 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **273396-82-0** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(2-hydroxy-1,1-dimethylethyl)oxidoimino]methyl]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H33 N O4

SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 38 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **251086-09-6** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methy
l]-, acetate (ester) (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H33 N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1947 TO DATE)
3 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 39 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **243457-35-4** REGISTRY
CN Phenol, 4-[(hexyloxidoimino)methyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H23 N O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 40 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **198695-58-8** REGISTRY
CN Phenol, 4-[[(1,1-dimethylethyl)oxidoimino]methyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H19 N O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1947 TO DATE)
3 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 41 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **165047-84-7** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[oxido(1,1,3,3-tetramethylbutyl)imino]methyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1,3,3-tetramethylbutyl)imino]methyl]-, N-oxide
FS 3D CONCORD
MF C23 H39 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 42 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **151166-75-5** REGISTRY
CN Benzaldehyde, 3,5-bis(1,1-dimethylethyl)-4-(methoxymethoxy)- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C17 H26 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1947 TO DATE)
13 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 43 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **124956-04-3** REGISTRY
CN Benzaldehyde, 3,5-bis(1,1-dimethylethyl)-4-[(2-methoxyethoxy)methoxy]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H30 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1947 TO DATE)
6 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 44 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **93933-61-0** REGISTRY
CN Phenol, 4-[[(1,1-dimethylethyl)oxidoimino]methyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 4-[[(1,1-dimethylethyl)imino]methyl]-2,6-dimethyl-, N-oxide
FS 3D CONCORD
DR 165047-87-0
MF C13 H19 N O2
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1947 TO DATE)
6 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 45 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **87133-21-9** REGISTRY
CN Benzaldehyde, 4-(acetyloxy)-3,5-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H24 O3
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1947 TO DATE)
4 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 46 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **29211-05-0** REGISTRY
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)oxidoimino]methyl]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Nitrone, N-tert-butyl-.alpha.-(3,5-di-tert-butyl-4-hydroxyphenyl)- (8CI)
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[(1,1-dimethylethyl)imino]methyl]-, N-oxide
FS 3D CONCORD
DR 165047-86-9
MF C19 H31 N O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1947 TO DATE)
13 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 47 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **25100-12-3** REGISTRY

CN Cyclohexanamine, N-hydroxy-, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydroxylamine, N-cyclohexyl-, hydrochloride (8CI)
OTHER NAMES:
CN Cyclohexylhydroxyamine hydrochloride
CN Cyclohexylhydroxylammonium chloride
CN N-Cyclohexylhydroxylamine hydrochloride
CN N-Hydroxycyclohexanamine hydrochloride
DR 72762-44-8
MF C6 H13 N O . Cl H
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (2211-64-5)



● HCl

47 REFERENCES IN FILE CA (1947 TO DATE)
47 REFERENCES IN FILE CAPLUS (1947 TO DATE)

L12 ANSWER 48 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **16649-50-6** REGISTRY
CN 2-Propanamine, N-hydroxy-2-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydroxylamine, N-tert-butyl- (6CI, 8CI)
OTHER NAMES:
CN 2-Hydroxylamino-2-methylpropane
CN N-Hydroxy-tert-butylamine
CN N-t-Butylhydroxylamine
CN N-tert-Butylhydroxylamine
CN tert-Butylhydroxylamine
FS 3D CONCORD
MF C4 H11 N O
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMINFORMRX, IFICDB, IFIPAT, IFIUDB, MEDLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

HO—NH—Bu-t

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

181 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
181 REFERENCES IN FILE CAPLUS (1947 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 49 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **5100-34-5** REGISTRY
CN Propanoic acid, 3-isocyanato-, ethyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN Propionic acid, 3-isocyanato-, ethyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN Ethyl 3-isocyanatopropanoate
CN Ethyl 3-isocyanatopropionate
FS 3D CONCORD
MF C6 H9 N O3
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

54 REFERENCES IN FILE CA (1947 TO DATE)
54 REFERENCES IN FILE CAPLUS (1947 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 50 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **5080-22-8** REGISTRY
CN 2-Propanamine, N-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydroxylamine, N-isopropyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN Isopropylhydroxylamine
CN N-Hydroxy-2-propanamine
CN N-Isopropylhydroxylamine
FS 3D CONCORD
MF C3 H9 N O
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMLIST, CIN, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

140 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
141 REFERENCES IN FILE CAPLUS (1947 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 51 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **3970-21-6** REGISTRY
CN Ethane, 1-(chloromethoxy)-2-methoxy- (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN .beta.-Methoxyethoxymethyl chloride
CN 1-(Chloromethoxy)-2-methoxyethane
CN 2,5-Dioxahexyl chloride
CN 2-(Chloromethoxy)ethoxymethane

CN 2-Methoxyethoxymethyl chloride
CN Chloromethyl 2-methoxyethyl ether
CN Methoxyethoxymethyl chloride
FS 3D CONCORD
MF C4 H9 Cl O2
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, MEDLINE, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

594 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
595 REFERENCES IN FILE CAPLUS (1947 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 52 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **2949-22-6** REGISTRY
CN Acetic acid, isocyanato-, ethyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Carbethoxymethyl isocyanate
CN Ethoxycarbonylmethyl isocyanate
CN Ethyl isocyanatoacetate
CN Isocyanatoacetic acid ethyl ester
FS 3D CONCORD
MF C5 H7 N O3
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, IFICDB, IFIPAT, IFIUDB, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

286 REFERENCES IN FILE CA (1947 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
286 REFERENCES IN FILE CAPLUS (1947 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 53 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **2211-64-5** REGISTRY
CN Cyclohexanamine, N-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydroxylamine, N-cyclohexyl- (6CI, 7CI, 8CI)
OTHER NAMES:
CN Cyclohexylhydroxylamine
CN N-Cyclohexylhydroxylamine

CN N-Hydroxycyclohexanamine
CN N-Hydroxycyclohexylamine
FS 3D CONCORD
MF C6 H13 N O
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, IPA, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

188 REFERENCES IN FILE CA (1947 TO DATE)
189 REFERENCES IN FILE CAPLUS (1947 TO DATE)
40 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 54 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **1620-98-0** REGISTRY
CN Benzaldehyde, 3,5-bis(1,1-dimethylethyl)-4-hydroxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzaldehyde, 3,5-di-tert-butyl-4-hydroxy- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2,6-Di-tert-Butyl-4-formylphenol
CN 3,5-Bis(1,1-dimethylethyl)-4-hydroxybenzaldehyde
CN 3,5-Di-tert-butyl-4-hydroxybenzaldehyde
CN 4-Formyl-2,6-di-tert-butylphenol
CN 4-Hydroxy-3,5-di-tert-butylbenzaldehyde
FS 3D CONCORD
MF C15 H22 O2
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, HODOC*, IFICDB, IFIPAT, IFIUDB, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

585 REFERENCES IN FILE CA (1947 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
587 REFERENCES IN FILE CAPLUS (1947 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 55 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN

RN **1122-60-7** REGISTRY
CN Cyclohexane, nitro- (8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Nitrocyclohexane
FS 3D CONCORD
MF C6 H11 N O2
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CSCHEM, DETHERM*, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

589 REFERENCES IN FILE CA (1947 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
589 REFERENCES IN FILE CAPLUS (1947 TO DATE)
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 56 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **111-36-4** REGISTRY
CN Butane, 1-isocyanato- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Isocyanic acid, butyl ester (6CI, 8CI)
OTHER NAMES:
CN 1-Isocyanatobutane
CN Butyl isocyanate
CN n-Butyl isocyanate
FS 3D CONCORD
MF C5 H9 N O
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM*, DIPPR*, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1680 REFERENCES IN FILE CA (1947 TO DATE)
103 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1685 REFERENCES IN FILE CAPLUS (1947 TO DATE)
25 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 57 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN

RN **110-78-1** REGISTRY
CN Propane, 1-isocyanato- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Isocyanic acid, propyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN 1-Isocyanatopropane
CN 1-Propyl isocyanate
CN n-Propyl isocyanate
CN Propyl isocyanate
FS 3D CONCORD
MF C4 H7 N O
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, DETHERM*, HODOC*, IFICDB, IFIPAT, IFIUDB, NIOSHTIC, PIRA, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

834 REFERENCES IN FILE CA (1947 TO DATE)
27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
840 REFERENCES IN FILE CAPLUS (1947 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 58 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **108-24-7** REGISTRY
CN Acetic acid, anhydride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic anhydride (8CI)
OTHER NAMES:
CN 8: PN: US20030096775 PAGE: 17 claimed sequence
CN 8: PN: US20030105041 PAGE: 16 claimed sequence
CN 8: PN: US20030114401 PAGE: 17 claimed sequence
CN 8: PN: WO03040320 PAGE: 50 claimed sequence
CN 8: PN: WO03040321 PAGE: 52 claimed sequence
CN 8: PN: WO03040328 PAGE: 51 claimed sequence
CN 8: PN: WO03041657 PAGE: 51 claimed sequence
CN 8: PN: WO03042360 PAGE: 50 claimed sequence
CN 8: PN: WO03044163 PAGE: 67 claimed sequence
CN 8: PN: WO03046132 PAGE: 52 claimed sequence
CN 8: PN: WO03050246 PAGE: 51 claimed sequence
CN 98: PN: US20030113914 PAGE: 17 claimed sequence
CN Acetic oxide
CN Acetyl acetate
CN Acetyl anhydride
CN Acetyl ether
CN Acetyl oxide
CN Ethanoic anhydride
FS 3D CONCORD
MF C4 H6 O3
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, DIPPR*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA,

ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Ac—O—Ac

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13889 REFERENCES IN FILE CA (1947 TO DATE)
350 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
13935 REFERENCES IN FILE CAPLUS (1947 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 59 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **107-30-2** REGISTRY
CN Methane, chloromethoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ether, chloromethyl methyl (6CI, 8CI)
OTHER NAMES:
CN .alpha.,.alpha.-Dichlorodimethyl ether
CN Chlorodimethyl ether
CN Chloromethoxymethane
CN Chloromethyl methyl ether
CN Methoxychloromethane
CN Methoxymethyl chloride
CN Methyl chloromethyl ether
CN Monochlorodimethyl ether
CN Monochloromethyl methyl ether
FS 3D CONCORD
MF C2 H5 Cl O
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, DIPPR*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PDLCOM*, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Cl—CH_2—O—CH_3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2679 REFERENCES IN FILE CA (1947 TO DATE)
132 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2682 REFERENCES IN FILE CAPLUS (1947 TO DATE)
63 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 60 OF 60 REGISTRY COPYRIGHT 2003 ACS on STN
RN **97-72-3** REGISTRY
CN Propanoic acid, 2-methyl-, anhydride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Isobutyric anhydride (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2-Methylpropanoic anhydride
CN 2-Methylpropionic anhydride

CN Isobutanoic anhydride
CN Isobutyric acid anhydride
CN Isobutyryl anhydride
FS 3D CONCORD
MF C8 H14 O3
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, NIOSHTIC, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

744 REFERENCES IN FILE CA (1947 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
744 REFERENCES IN FILE CAPLUS (1947 TO DATE)
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> sel rn 3-5, 24-27
E61 THROUGH E67 ASSIGNED

=> fil medl hcapl biosis uspatf

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	104.16	392.18

FILE 'MEDLINE' ENTERED AT 12:11:23 ON 21 JUL 2003

FILE 'HCAPLUS' ENTERED AT 12:11:23 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:11:23 ON 21 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 12:11:23 ON 21 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s e61-67
L13 2 (273396-93-3/BI OR 273396-94-4/BI OR 273396-95-5/BI OR 273396-96-6/BI OR 452283-91-9/BI OR 452283-92-0/BI OR 452283-93-1/BI)

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 2 DUP REM L13 (0 DUPLICATES REMOVED)

=> d tot ibib abs

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:657919 HCAPLUS
DOCUMENT NUMBER: 137:195593
TITLE: Methods for the treatment of neuropathic pain by aryl nitrone compounds

INVENTOR(S): Waterbury, David; Wood, Paul L.; Khan, M. Amin; Upasani, Ravindra B.
PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002065993	A2	20020829	WO 2002-US758	20020108
WO 2002065993	A3	20021107		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002165274	A1	20021107	US 2002-43659	20020108

PRIORITY APPLN. INFO.: US 2001-260469P P 20010108
OTHER SOURCE(S): MARPAT 137:195593

AB Methods are disclosed for the treatment of neuropathic pain by aryl nitrone compds. Method involves administration of an effective neuropathic pain-treating dose of a pharmaceutical compn. (Markush structures are given). Substituted aryl nitrone compds. are useful as therapeutics for neuropathic pain conditions in mammals.

L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:384142 HCAPLUS
DOCUMENT NUMBER: 133:30572
TITLE: Preparation of 3,4,5-trisubstituted aryl nitrones for the treatment of inflammation-related conditions
INVENTOR(S): Waterbury, L. David; Wilcox, Allan L.; Carney, John M.; Mavandadi, Farah; Danielzadeh, Albert
PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032567	A1	20000608	WO 1999-US28479	19991201

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9915886	A	20010821	BR 1999-15886	19991201
EP 1135367	A1	20010926	EP 1999-962967	19991201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

US 6342523	B1	20020129	US 1999-452529	19991201

JP 2002531435	T2	20020924	JP 2000-585209		19991201
NO 2001002727	A	20010726	NO 2001-2727		20010601
US 2003078297	A1	20030424	US 2002-196800		20020715
PRIORITY APPLN. INFO.:			US 1998-110541P	A2	19981202
			WO 1999-US28479	W	19991201
			US 2001-857264	A1	20010907

OTHER SOURCE(S): MARPAT 133:30572
GI



I



II

AB The title compds. (I) [wherein R1 = C(W)R5, C(W)NR6R7, or CHR9XR8; R2 = alkyl or cycloalkylalkyl; R3 = H, (cyclo)alkyl, or aryl; R4, R5, and R8 = independently (un)substituted (cyclo)alkyl, (cyclo)alkenyl, or alkynyl; R6, R7, and R9 = independently H or (un)substituted (cyclo)alkyl, (cyclo)alkenyl, or alkynyl; W = O or S; X = O, S, S(O), or SO2] were prepd. by condensing trisubstituted benzaldehydes with hydroxylamines. For example, reaction of 4-acetoxy-3,5-di-tert-butylbenzaldehyde with tert-butylhydroxylamine gave II (74%). In in vitro assays, II did not inhibit cyclooxygenase-I (COX-1) and cyclooxygenase-2 (COX-2). Representative invention compds. were tested in a no. of assays and were effective for reducing the induction of prostaglandin E2 (PGE2) and/or effective in the carrageenan, adjuvant, and/or collagen assay. I are useful in the treatment of arthritis and other inflammation-related conditions and as anal. reagents for detecting free radicals.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.59	410.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

FILE 'REGISTRY' ENTERED AT 12:16:21 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUL 2003 HIGHEST RN 551897-78-0
DICTIONARY FILE UPDATES: 20 JUL 2003 HIGHEST RN 551897-78-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading aryl nitrone for neuropathic pain.str

L15 STRUCTURE UPLOADED

=> d
L15 HAS NO ANSWERS
L15 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l15
SAMPLE SEARCH INITIATED 12:16:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L16 0 SEA SSS SAM L15

=> s l15 full
FULL SEARCH INITIATED 12:17:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L17 0 SEA SSS FUL L15

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.55	559.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.30

FILE 'STNGUIDE' ENTERED AT 12:17:34 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 11, 2003 (20030711/UP).

=> fil medl hcapl biosis uspatf

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	559.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.30

FILE 'MEDLINE' ENTERED AT 12:20:35 ON 21 JUL 2003

FILE 'HCAPLUS' ENTERED AT 12:20:35 ON 21 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:20:35 ON 21 JUL 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 12:20:35 ON 21 JUL 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s inflammat? or antiinflammat?
L18 751121 INFLAMMAT? OR ANTIINFLAMMAT?

=> s neuropath?
L19 114667 NEUROPATH?

=> s l18 and l19
L20 10692 L18 AND L19

=> s l18 (S) l19
L21 5107 L18 (S) L19

=> s l18 (S) neuropathic pain
L22 880 L18 (S) NEUROPATHIC PAIN

=> s inflammation (S) neuropathic pain
L23 331 INFLAMMATION (S) NEUROPATHIC PAIN

=> dup rem l23
PROCESSING COMPLETED FOR L23
L24 293 DUP REM L23 (38 DUPLICATES REMOVED)

=> s l24 not py>2001
L25 113 L24 NOT PY>2001

=> focus
PROCESSING COMPLETED FOR L25
L26 113 FOCUS L25 1-

=> d ibib abs 1-5

L26 ANSWER 1 OF 113 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:26707 BIOSIS
DOCUMENT NUMBER: PREV200200026707
TITLE: Opioids in chronic pain.
AUTHOR(S): Przewlocki, Ryszard (1); Przewlocka, Barbara
CORPORATE SOURCE: (1) Department of Molecular Neuropharmacology, Institute of

Pharmacology, 12 Smetna Street, 31-343, Krakow: nfprzewl@cyf-kr.edu.pl Poland
SOURCE: European Journal of Pharmacology, (19 October, 2001) Vol. 429, No. 1-3, pp. 79-91. print.
ISSN: 0014-2999.
DOCUMENT TYPE: General Review
LANGUAGE: English
AB The advance in our understanding of the biogenesis of various endogenous opioid peptides, their anatomical distribution, and the characteristics of the multiple receptors with which they interact open a new avenue for understanding the role of opioid peptide systems in chronic pain. The main groups of opioid peptides: enkephalins, dynorphins and beta-endorphin derive from proenkephalin, prodynorphin and proopiomelanocortin, respectively. Recently, a novel group of peptides has been discovered in the brain and named endomorphins, endomorphin-1 and -2. They are unique in comparison with other opioid peptides by atypical structure and high selectivity towards the mu-opioid receptor. Another group, which joined the endogenous opioid peptide family in the last few years is the pronociceptin system comprising the peptides derived from this prohormone, acting at ORL1 receptors. Three members of the opioid receptor family were cloned in the early 1990s, beginning with the mouse delta-opioid receptor (DOR1) and followed by cloning of mu-opioid receptor (MOR1) and kappa-opioid receptor (KOR1). These three receptors belong to the family of seven transmembrane G-protein coupled receptors, and share extensive structural homologies. These opioid receptor and peptide systems are significantly implicated in antinociceptive processes. They were found to be represented in the regions involved in nociception and pain. The effects of opioids in animal models of inflammatory pain have been studied in great detail. **Inflammation** in the periphery influences the central sites and changes the opioid action. **Inflammation** increased spinal potency of various opioid receptor agonists. In general, the antinociceptive potency of opioids is greater against various noxious stimuli in animals with peripheral **inflammation** than in control animals. **Inflammation**-induced enhancement of opioid antinociceptive potency is characteristic predominantly for mu opioid receptors, since morphine elicits a greater increase in spinal potency of mu- than of delta- and kappa-opioid receptor agonists. Enhancement of the potency of mu-opioid receptor agonists during **inflammation** could arise from the changes occurring in opioid receptors, predominantly in affinity or number of the mu-opioid receptors. **Inflammation** has been shown to alter the expression of several genes in the spinal cord dorsal horn. Several studies have demonstrated profound alterations in the spinal PDYN system when there is peripheral **inflammation** or chronic arthritis. Endogenous dynorphin biosynthesis also increases under various conditions associated with **neuropathic pain** following damage to the spinal cord and injury of peripheral nerves. Interestingly, morphine lacks potent analgesic efficacy in **neuropathic pain**. A vast body of clinical evidence suggests that **neuropathic pain** is not opioid-resistant but only that reduced sensitivity to systemic opioids is observed in this condition, and an increase in their dose is necessary in order to obtain adequate analgesia. Reduction of morphine antinociceptive potency was postulated to be due to the fact that nerve injury reduced the activity of spinal opioid receptors or opioid signal transduction. Our recent study with endogenous ligands of the mu-opioid receptor, endomorphins, further complicates the issue, since endomorphins appear to be effective in **neuropathic pain**. Identification of the involved differences may be of importance to the understanding of the molecular mechanism of opioid action in **neuropathic pain**, as well as to the development of better and more effective drugs for the treatment of **neuropathic pain** in humans.

L26 ANSWER 2 OF 113 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:712313 HCAPLUS
DOCUMENT NUMBER: 127:357434

TITLE: Peripheral modulatory effects of catecholamines in inflammatory and neuropathic pain
AUTHOR(S): Raja, Srinivasa N.
CORPORATE SOURCE: Dep. Anesthesiol. Critical Care Med., Div. Pain Med., Johns Hopkins Hosp., Baltimore, MD, 21287-5354, USA
SOURCE: Advances in Pharmacology (San Diego) (1998), 42(Catecholamines), 567-571
CODEN: ADPHEL; ISSN: 1054-3589
PUBLISHER: Academic
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review, with 9 refs. discussing the role played by the sympathetic nervous system in pathol. states assocd. with pain and hyperalgesia, such as **inflammation** and **neuropathic pain**. Topics include sympathetic efferents in normal tissue, role of sympathetics in inflammed tissues, role of sympathetics in neuropathic pain, peripheral sympathetic-somatic coupling after partial nerve injury, and pharmacol. of animal models of sympathetically maintained pain.

L26 ANSWER 3 OF 113 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:587155 HCAPLUS
DOCUMENT NUMBER: 138:130997
TITLE: Fluoxetine, a selective serotonin reuptake inhibitor modulates inflammatory and neuropathic pain in the rat
AUTHOR(S): Pal Singh, Vijay; Jain, Naveen K.; Kulkarni, S. K.
CORPORATE SOURCE: Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160 014, India
SOURCE: Inflammopharmacology (2001), 9(3), 219-228
CODEN: IAOAES; ISSN: 0925-4692
PUBLISHER: VSP BV
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The clin. usefulness of classical tricyclic antidepressants has been indicated in a variety of neuropathic pain. The role of selective serotonin reuptake inhibitors (SSRIs) is, however, controversial in pain control. The present study was aimed at evaluating the efficacy of an SSRI, fluoxetine, in **neuropathic pain** involving peripheral (carrageenan-induced **inflammation**) and central sensitization (spinal nerve ligation) in rats. Fluoxetine was also assessed for antinociceptive and antiphlogistic effect against acetic acid-induced chemonociception in mice and carrageenan-induced inflammation. Fluoxetine (100-400 .mu.g, intraplantar administration) failed to attenuate either hyperalgesia or cold allodynia in any of the tests employed. Fluoxetine dose dependently increased paw vol. in the absence or presence of an inflammatory stimulus which was not reversed by indomethacin (10 mg/kg, p.o). Fluoxetine was ineffective in reducing hyperalgesia and allodynia assocd. with the rat models. However, fluoxetine dose dependently decreased acetic acid-induced writhings. The results indicated that 5-HT plays a differential role in pain modulation and may not be playing a major role in the maintenance of hyperalgesia and allodynia in the rat models.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 113 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:88979 BIOSIS
DOCUMENT NUMBER: PREV200100088979
TITLE: Gabapentin attenuates the inflammation-induced increase in the release of neuropeptides from rat spinal cord slices.
AUTHOR(S): Fehrenbacher, J. C. (1); Eckerle, C.; Vasko, M. R.
CORPORATE SOURCE: (1) Indiana University School of Medicine, Indianapolis, IN USA
SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-453.8. print.

Meeting Info.: 30th Annual Meeting of the Society of Neuroscience New Orleans, LA, USA November 04-09, 2000 Society for Neuroscience
. ISSN: 0190-5295.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English
AB Gabapentin reduces nociceptive behaviors in animal models of **inflammation** and relieves **neuropathic pain** in humans but has minimal effects on acute pain tests. To ascertain whether gabapentin's antinociceptive actions could be mediated by an effect on sensory neurons, we examined whether this anticonvulsant could attenuate the effects of **inflammation** on release of immunoreactive substance P (iSP) and calcitonin-gene related peptide (iCGRP) from sensory terminals in the spinal cord. Unilateral **inflammation** was induced in Sprague-Dawley rats by injecting 150 mul of a Freund's adjuvant (CFA) solution into one hindpaw. Five days later, spinal cords were removed, divided midsagitally, chopped and superfused with Kreb'sbicarbonate buffer in the presence and absence of gabapentin. Peptide release was evoked with 500 nM capsaicin and iSP and iCGRP measured by radioimmunoassay. When injection of CFA produced all increase in paw size of 3.2 mm. **inflammation** resulted in an 2-fold increase in the capsaicin-evoked release of iSP and iCGRP from spinal cord compared to tissue from the noninflamed side. Exposing the spinal cord tissue to 10 muM gabapentin completely abolished the **inflammation** -induced augmentation of the capsaicin-evoked peptide release. Evoked release of iSP and iCGRP was reduced from 2.2 +- 0.6 to 0.4 +- 0.1 % of total content/9 min and from 5.4 +- 1.1 to 1.9 +- 0.3 % of total content 9 min. respectively. In contrast, treatment with either 10 muM or 100 muM gabapentin did not significantly alter capsaicin-evoked peptide release from spinal cord tissue of non-inflamed rats. These results support the notion that gabapentin alters the sensitivity of sensory neurons that occurs secondary to **inflammation** without affecting neurons under control conditions. These findings are consistent with the observations that gabapentin is effective in reducing inflammatory or **neuropathic pain** and not acute pain.

L26 ANSWER 5 OF 113 MEDLINE on STN
ACCESSION NUMBER: 97112135 MEDLINE
DOCUMENT NUMBER: 97112135 PubMed ID: 8953862
TITLE: N-methyl-D-aspartate (NMDA) receptor and pain.
AUTHOR: Yamamoto T
CORPORATE SOURCE: Department of Anesthesiology, School of Medicine, Chiba University.
SOURCE: MASUI. JAPANESE JOURNAL OF ANESTHESIOLOGY, (1996 Nov) 45 (11) 1312-8. Ref: 24
Journal code: 0413707. ISSN: 0021-4892.
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: Japanese
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199701
ENTRY DATE: Entered STN: 19970219
Last Updated on STN: 19970219
Entered Medline: 19970121
AB It has been shown that an excitatory amino acid, such as glutamate and aspartate, plays an important role in the spinal nociceptive transmission. NMDA receptor is one of the receptors of excitatory amino acids. Glutamate is present in the terminals of small diameter primary afferent fibers, as well as in dorsal horn interneurons. It has been reported that NMDA receptor is not located postsynaptic to primary afferent input; rather it mediates excitation evoked by glutamate-releasing interneurons. Activation of chemosensitive afferents with chemical irritants generates a

state of central sensitization in the spinal cord, and this hyperexcitability is blocked by NMDA antagonist. These data suggested that activation of chemosensitive afferents induces release of glutamate which activates NMDA receptor in dorsal horn interneurons, and that this NMDA receptor activation induces spinal sensitization. It has been suggested that this spinal sensitization plays an important role in the maintenance of **neuropathic pain** and hyperalgesia during **inflammation**. In the clinical trial, epidural administration of NMDA antagonist attenuated the level of allodynia in patients with postherpetic neuralgia. I think that spinal sensitization induced by NMDA receptor activation is the key mechanism to maintain **neuropathic pain** and hyperalgesia during **inflammation**.

=> s l26 and lupus
L27 4 L26 AND LUPUS

=> d ibib abs tot

L27 ANSWER 1 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2001:52054 USPATFULL
TITLE: Substituted imidazoles useful in the treatment of inflammatory diseases
INVENTOR(S): Beers, Scott A., Flemington, NJ, United States
Malloy, Elizabeth A., Flemington, NJ, United States
Wachter, Michael P., Bloomsbury, NJ, United States
Wu, Wei, Somerville, NJ, United States
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214830	B1	20010410
APPLICATION INFO.:	US 1999-295156		19990420 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-62304, filed on 17 Apr 1998, now patented, Pat. No. US 5965583
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a series of substituted imidazoles of Formula I ##STR1##

pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention inhibit the production of a number of inflammatory cytokines, and are useful in the treatment of diseases associated with overproduction of inflammatory cytokines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 2 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2000:61584 USPATFULL
TITLE: Application of botulinum toxin to the management of neurogenic inflammatory disorders
INVENTOR(S): First, Eric R., 52-N-St., South Boston, MA, United States 02127

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6063768		20000516
APPLICATION INFO.:	US 1997-923884		19970904 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20400P	19960906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: Engellenner, Thomas J.Nutter, McClennen & Fish LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the use of at least one serotype or a combination of serotypes of Botulinum neurotoxin either alone or in combination with other peptides or fusion proteins, that when administered in a safe and effective amount, antagonize and therefore decrease or block inflammation induced by the neurogenic mechanisms underlying or associated with inflammatory disorders, in particular, arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 3 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2000:34566 USPATFULL
TITLE: 2-substituted imidazoles useful in the treatment of inflammatory diseases
INVENTOR(S): Beers, Scott A., Flemington, NJ, United States
Malloy, Elizabeth A., Flemington, NJ, United States
Wachter, Michael P., Bloomsbury, NJ, United States
Wu, Wei, Somerville, NJ, United States
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6040320		20000321
APPLICATION INFO.:	US 1998-106698		19980629 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane
LEGAL REPRESENTATIVE: Harbour, John
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1075
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to substituted imidazoles of Formula I ##STR1## pharmaceutical compositions containing them, methods of using them and intermediates useful in their manufacture. The compounds of the invention modulate the production of a number of inflammatory cytokines, and are useful in the treatment of diseases associated with the production of inflammatory cytokines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 4 OF 4 USPATFULL on STN
ACCESSION NUMBER: 1999:124919 USPATFULL
TITLE: Substituted imidazoles useful in the treatment of inflammatory disease
INVENTOR(S): Beers, Scott A., Flemington, NJ, United States
Malloy, Elizabeth A., Flemington, NJ, United States
Wachter, Michael P., Bloomsbury, NJ, United States
Wu, Wei, Somerville, NJ, United States
PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5965583		19991012	
APPLICATION INFO.:	US 1998-62304		19980417	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-44252P	19970427	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fan, Jane
LEGAL REPRESENTATIVE: Harbour, John
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a series of substituted imidazoles of Formula I ##STR1## pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention inhibit the production of a number of inflammatory cytokines, and are useful in the treatment of diseases associated with overproduction of inflammatory cytokines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.23	585.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-2.60

FILE 'STNGUIDE' ENTERED AT 12:24:00 ON 21 JUL 2003

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 11, 2003 (20030711/UP).

=> FIL MEDL HCAPL BIOSIS USPATF

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	586.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.60

FILE 'MEDLINE' ENTERED AT 12:26:03 ON 21 JUL 2003

FILE 'HCAPLUS' ENTERED AT 12:26:03 ON 21 JUL 2003

FILE 'BIOSIS' ENTERED AT 12:26:03 ON 21 JUL 2003

FILE 'USPATFULL' ENTERED AT 12:26:03 ON 21 JUL 2003

```
=> s acute brachial neuritis
L28          10 ACUTE BRACHIAL NEURITIS

=> s neuritis
L29       15329 NEURITIS

=> s l29 and l18
L30        2827 L29 AND L18

=> s l29 (s) l18
L31        1349 L29 (S) L18

=> s l31 and l19
L32         517 L31 AND L19

=> s l31 (S) l19
L33         157 L31 (S) L19

=> dup rem l33
PROCESSING COMPLETED FOR L33
L34         145 DUP REM L33 (12 DUPLICATES REMOVED)

=> s l34 and neuropathic pain
L35          23 L34 AND NEUROPATHIC PAIN

=> focus
PROCESSING COMPLETED FOR L35
L36          23 FOCUS L35 1-

=> d ibib abs 1-5

L36  ANSWER 1 OF 23  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2002:977582  HCAPLUS
DOCUMENT NUMBER:          138:37450
TITLE:                    Ras-MEK-ERK1/2 signaling pathway in the production of
                          inflammatory and neuropathic pain
                          and uses for analgesic screening
INVENTOR(S):              Levine, Jon David; Messing, Robert O.
PATENT ASSIGNEE(S):       The Regents of the University of California, USA
SOURCE:                   PCT Int. Appl., 134 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002102232      A2   20021227       WO 2002-US19107  20020614
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003008807      A1   20030109       US 2002-173332   20020614
PRIORITY APPLN. INFO.:                     US 2001-298491P  P  20010614
AB   This invention pertains to the discovery of a novel pathway that mediates
     hyperalgesia, neuropathic pain, and inflammatory pain.
     This pathway is a third independent pathway that involves activation of
     extracellular signal-regulated kinases (ERKs) 1 and 2.  The pathway
```

comprises a Ras-MEK-ERK1/2 cascade that acts independent of PKA or PKC.epsilon. as a novel signaling pathway for the prodn. of inflammatory (and **neuropathic**) **pain**. This pathway presents numerous targets for a new class of analgesic agents.

L36 ANSWER 2 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2003:30977 USPATFULL
TITLE: Method for treating **neuropathic pain** and pharmaceutical preparation therefor
INVENTOR(S): Lavand'Homme, Patricia, Brussel, BELGIUM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003022926	A1	20030130	
APPLICATION INFO.:	US 2002-141532	A1	20020507	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-289063P	20010507	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for a sustained treatment and/or prophylaxis of **neuropathic pain** in mammal comprising administering by peripheral nerve injection a **neuropathic pain** relieving composition comprising an alpha-2-adrenergic agonist.

The invention further relates to the use of an alpha-2-adrenergic agonist for the preparation of an injectable medicament for the sustained treatment and/or prophylaxis of **neuropathic pain** in mammal by peripheral nerve block.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 3 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2000:50711 USPATFULL
TITLE: Treatment of **neuropathic pain**
INVENTOR(S): Fairbanks, Carolyn A., NE. Rochester, MN, United States
Wilcox, George L., N. Golden Valley, MN, United States
Laughin, Tinna M., Anoka, MN, United States
PATENT ASSIGNEE(S): Solvay Pharmaceuticals GmbH, Hannover, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6054461		20000425	
APPLICATION INFO.:	US 1998-152343		19980914	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Evenson, McKeown, Edwards & Lenahan, P.L.L.C.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of relieving **neuropathic pain** uses

moxonidine and its physiologically compatible acid-addition salts for the treatment and/or prophylaxis of **neuropathic pain** . A composition comprising an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier, is administered to a subject in need of such treatment. The composition may be administered intrathecally.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 4 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2002:295225 USPATFULL
TITLE: Use of aryl nitrone compounds in methods for treating **neuropathic pain**
INVENTOR(S): Waterbury, L. David, San Carlos, CA, UNITED STATES
Wood, Paul L., Morgan Hill, CA, UNITED STATES
Khan, M. Amin, Morgan Hill, CA, UNITED STATES
Upasani, Ravindra B., San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002165274	A1	20021107	
APPLICATION INFO.:	US 2002-43659	A1	20020108	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-260469P	20010108	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: William H. Benz, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 1813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 3,4,5-trisubstituted aryl nitrone compounds having the formula: ##STR1##

where R.sup.1--R.sup.4 are as defined in the specification are useful as therapeutics for **neuropathic pain** conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L36 ANSWER 5 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2003:11103 USPATFULL
TITLE: Novel signaling pathway for the production of inflammatory pain and neuropathy
INVENTOR(S): Levine, Jon David, San Francisco, CA, UNITED STATES
Messing, Robert O., Foster City, CA, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003008807	A1	20030109	
APPLICATION INFO.:	US 2002-173332	A1	20020614	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-298491P	20010614	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501

NUMBER OF CLAIMS: 141
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Page(s)
LINE COUNT: 4135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to the discovery of a novel pathway that mediates hyperalgesia, **neuropathic pain**, and inflammatory pain. This pathway is a third independent pathway that involves activation of extracellular signal-regulated kinases (ERKs) 1 and 2. The pathway comprises a Ras-MEK-ERK1/2 cascade that acts independent of PKA or PKC.epsilon. as a novel signaling pathway for the production of inflammatory (and **neuropathic**) **pain**. This pathway presents numerous targets for a new class of analgesic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ti tot l35

L35 ANSWER 1 OF 23 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Ras-MEK-ERK1/2 signaling pathway in the production of inflammatory and **neuropathic pain** and uses for analgesic screening

L35 ANSWER 2 OF 23 HCAPLUS COPYRIGHT 2003 ACS on STN
TI Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury

L35 ANSWER 3 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI The Effect of Neuritis and Inflammatory Substances on Slowly Conducting Afferent Fibers.

L35 ANSWER 4 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation.

L35 ANSWER 5 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Infiltration of immune cells and TNFalpha into the rat sciatic nerve in an experimental neuritis that evokes **neuropathic pain**.

L35 ANSWER 6 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI **Neuropathic pain** from an experimental neuritis of the rat sciatic nerve.

L35 ANSWER 7 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
TI Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies.

L35 ANSWER 8 OF 23 USPATFULL on STN
TI 1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

L35 ANSWER 9 OF 23 USPATFULL on STN
TI Methods of treating cytokine mediated diseases

L35 ANSWER 10 OF 23 USPATFULL on STN
TI 1,4-disubstituted benzo-fused cycloalkyl urea compounds

L35 ANSWER 11 OF 23 USPATFULL on STN
TI Human ion channels

L35 ANSWER 12 OF 23 USPATFULL on STN
TI Methods of treating cytokine mediated diseases

L35 ANSWER 13 OF 23 USPATFULL on STN

TI 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission

L35 ANSWER 14 OF 23 USPATFULL on STN
TI Use of certain drugs for treating nerve root injury

L35 ANSWER 15 OF 23 USPATFULL on STN
TI Method for treating **neuropathic pain** and pharmaceutical preparation therefor

L35 ANSWER 16 OF 23 USPATFULL on STN
TI Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels

L35 ANSWER 17 OF 23 USPATFULL on STN
TI Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels

L35 ANSWER 18 OF 23 USPATFULL on STN
TI Novel signaling pathway for the production of inflammatory pain and neuropathy

L35 ANSWER 19 OF 23 USPATFULL on STN
TI 1-(adamantyl)amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission

L35 ANSWER 20 OF 23 USPATFULL on STN
TI Use of aryl nitrone compounds in methods for treating **neuropathic pain**

L35 ANSWER 21 OF 23 USPATFULL on STN
TI Capsaicin receptor ligands

L35 ANSWER 22 OF 23 USPATFULL on STN
TI Adamantanecarboximidamide derivatives and their use as NMDA antagonists

L35 ANSWER 23 OF 23 USPATFULL on STN
TI Treatment of **neuropathic pain**

=> d ibib abs 23

L36 ANSWER 23 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2001:112371 USPATFULL

TITLE: Adamantanecarboximidamide derivatives and their use as NMDA antagonists

INVENTOR(S): Monck, Nathaniel Julius Thomas, Berkshire, United Kingdom
Gillespie, Roger John, Berkshire, United Kingdom
Bird, Andrew James, Berkshire, United Kingdom

PATENT ASSIGNEE(S): Vernalis Research Limited, Wokingham, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6262106	B1	20010717	
	WO 9938841		19990805	
APPLICATION INFO.:	US 2000-600168		20000913	(9)
	WO 1999-GB321		19990101	
			20000913	PCT 371 date
			20000913	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-2225	19980202

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Barts, Samuel
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 809
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB ##STR1##

The compound of the above formula wherein R1-R5 are independently selected from hydrogen, alkyl and aryl and prodrugs thereof; and pharmaceutically acceptable salts thereof; and use of the compounds in therapy, particularly for treatment of a condition generally associated with abnormalities in glutamtergic transmission.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s neuralgia
L37 14916 NEURALGIA

=> s l27 and l18
L38 4 L27 AND L18

=> d

L38 ANSWER 1 OF 4 USPATFULL on STN
AN 2001:52054 USPATFULL
TI Substituted imidazoles useful in the treatment of **inflammatory** diseases
IN Beers, Scott A., Flemington, NJ, United States
Malloy, Elizabeth A., Flemington, NJ, United States
Wachter, Michael P., Bloomsbury, NJ, United States
Wu, Wei, Somerville, NJ, United States
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)
PI US 6214830 B1 20010410
AI US 1999-295156 19990420 (9)
RLI Division of Ser. No. US 1998-62304, filed on 17 Apr 1998, now patented, Pat. No. US 5965583
DT Utility
FS Granted
LN.CNT 997
INCL INCLM: 514/256.000
INCLS: 544/333.000
NCL NCLM: 514/256.000
NCLS: 544/333.000
IC [7]
ICM: C07D403-04
ICS: A61K031-506
EXF 514/256; 544/333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.63	632.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-3.25

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:41:42 ON 21 JUL 2003

ACCESSION NUMBER: 1977:499910 CAPLUS
DOCUMENT NUMBER: 87:99910
TITLE: Pancreatic islet cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent **autoimmune disease** and HLA type
AUTHOR(S): Vaughan, H.; Irvine, W. J.; McCallum, C. J.; Gray, R. S.; Campbell, C. J.; Duncan, L. J. P.; Farquhar, J.; Morris, P. J.
CORPORATE SOURCE: Dep. Endocrinol., R. Infirm., Edinburgh, Scot.
SOURCE: J. Endocrinol. (1977), 73(3), 40P(02)-41P
CODEN: JOENAK
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In both insulin-dependent and insulin-independent diabetics (IDD and IID, resp.) the prevalence of humoral pancreatic islet cell antibodies (ICA6) was dependent on the duration of diabetes and showed no correlation with the **patient's** age. The ICA6 persisted for longer in IDD with assocd. overt organ-specific autoimmune disease than in those without such assocd. disease. The prevalence of HLA-B8 was increased in ICA6-pos. **patients** (61%) compared with **patients** in whom ICA6 was neg. within 3 months of diagnosis (35%) and in controls (28%). HLA-B7 was less prevalent in ICA6-pos. **patients** compared with controls. Autoimmunity to pancreatic islet cell may, therefore, provide a better basis for the classification of idiopathic diabetes than the age of onset or type of treatment required.

L36 ANSWER 36 OF 47 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1985:5798 CAPLUS
DOCUMENT NUMBER: 102:5798
TITLE: Ring-chain isomerism of N-(1-carboxyalkyl)nitrones. I.
C-Aryl-N-(1-carboxylalkyl)nitrones
AUTHOR(S): Kliegel, Wolfgang; Graumann, Juergen
CORPORATE SOURCE: Inst. Pharm. Chem., Tech. Univ. Braunschweig, Braunschweig, D-3300, Fed. Rep. Ger.
SOURCE: Liebigs Ann. Chem. (1984), (9), 1545-62
CODEN: LACHDL; ISSN: 0170-2041
DOCUMENT TYPE: Journal
LANGUAGE: German
GI


II


III


IV

AB RCH:N+(O-)CR1R2CO2H [I; R = (un)substituted Ph; R1 = H, Me, Ph; R2 = H, Me, Et; R1R2 = (CH2)4, (CH2)5] were prepd. by alkylation of (Z)-RCH:NOH with R1R2CBrCO2H or by condensation of HONHCR1R2CO2H with RCHO. The ring-chain isomerism between nitrone I and oxazolidine II could not be proven spectroscopically. Acylating I with (Ph2B)2O gave boron chelates III of the open-chain nitrone form, while acylating with carboxylic acids or isocyanates gave oxazolidones IV [R3 = Me, 3,5-(O2N)2C6H3, 3-ClC6H4NH].

Alkylating I with PhCOCH2Br gave esters RCH:N+(O-)CR1R2CO2CH2COPh.

IT **17556-16-0P 86737-36-2P 93562-94-8P**
93562-95-9P 93563-03-2P 93563-06-5P
RL: RCT (Reactant); SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and cyclization of, with oxybis(diphenylborane))

RN 17556-16-0 CAPLUS
CN Glycine, N-[(4-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)



RN 86737-36-2 CAPLUS
CN L-Alanine, N-[(4-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 93562-94-8 CAPLUS
CN Benzeneacetic acid, .alpha.-[[(4-methoxyphenyl)methylene]oxidoamino]- (9CI) (CA INDEX NAME)



RN 93562-95-9 CAPLUS
CN Glycine, N-[(2-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)



RN 93563-03-2 CAPLUS
CN L-Alanine, N-[(2-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 93563-06-5 CAPLUS
CN Glycine, N-[(4-hydroxy-3-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)



IT **93563-07-6P**
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of)
RN 93563-07-6 CAPLUS
CN Glycine, N-[(3-hydroxy-4-methoxyphenyl)methylene]-, N-oxide (9CI) (CA INDEX NAME)



L36 ANSWER 32 OF 47 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1987:515572 CAPLUS
DOCUMENT NUMBER: 107:115572
TITLE: Intramolecular 1,3-dipolar cycloaddition reactions. I.
Thermochemical reactivities and regioselectivities of 4-substituted phenyl(N-4-pentenyl)nitrones
AUTHOR(S): Chen, Qinghua; Meng, Min
CORPORATE SOURCE: Dep. Chem., Beijing Norm. Univ., Beijing, Peop. Rep. China
SOURCE: Huaxue Xuebao (1986), 44(9), 927-33
CODEN: HHHPA4; ISSN: 0567-7351
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 107:115572
GI



I



VI



VII

AB Refluxing nitrones I [R = NO2 (II), Br (III), H (IV), MeO (V)] in toluene for 24 h gave 54-80% cycloadducts VI and VII (VI/VII = 2). The thermochem. reactivity is in the order of II > III > IV > V.

IT **109830-20-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and cycloaddn. reaction of)

RN 109830-20-8 CAPLUS
CN 4-Penten-1-amine, N-[(4-methoxyphenyl)methylene]-, N-oxide, (Z)- (9CI) (CA INDEX NAME)



IT **109830-28-6P**
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of)
RN 109830-28-6 CAPLUS
CN 3-Penten-1-amine, N-[(4-methoxyphenyl)methylene]-, N-oxide, (Z,E)- (9CI)
(CA INDEX NAME)



L36 ANSWER 31 OF 47 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1988:549392 CAPLUS
DOCUMENT NUMBER: 109:149392
TITLE: Synthesis of 2-alkyl-3-aryloxaziridines
AUTHOR(S): Kloc, Krystian; Kubicz, Elzbieta; Mlochowski, Jacek; Syper, Ludwik
CORPORATE SOURCE: Inst. Org. Phys. Chem., Tech. Univ. Wroclaw, Wroclaw, PL-50-370, Pol.
SOURCE: Synthesis (1987), (12), 1084-7
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:149392
GI



I II

AB Imination of RCHO (R = p-tolyl, p-anisyl, m-HOC6H4, p-XC6H4, X = Cl, Br, 3,4-(MeO)2C6H3, p-Et2NC6H4, naphthyl, 2-furyl, pyridyl, etc.) with Me3CNH2 in the presence of mol. sieves gave 66-99% .apprx.20 azomethines I, which were oxidized with m-ClC6H4CO3H and Na2CO3 in CHCl3 to give 21-66% .apprx.20 oxaziridines II.

IT **72995-53-0P**
RL: PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and spectra of)

RN 72995-53-0 CAPLUS
CN 2-Propanamine, N-[(2,4-dimethoxyphenyl)methylene]-2-methyl-, N-oxide (9CI)
(CA INDEX NAME)



L36 ANSWER 20 OF 47 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1992:193591 CAPLUS
DOCUMENT NUMBER: 116:193591
TITLE: Synthesis and characterization of phenyl-substituted C-phenyl-N-tert-butylnitrones and some of their radical adducts
AUTHOR(S): Hinton, Randall D.; Janzen, Edward G.
CORPORATE SOURCE: Natl. Biomed. Cent. Spin Trapp. Free Radicals, Oklahoma Med. Res. Found., Oklahoma City, OK, 73104, USA
SOURCE: J. Org. Chem. (1992), 57(9), 2646-51
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Synthesis of C-phenyl-N-tert-butylnitrone (PBN) and several of its analogs with substituents in the 2-, 3-, or 4-position on the Ph ring is described. While a one-pot redn./condensation method proved suitable for most compds., it was necessary to prep. some examples by direct condensation or through oxidn. of the appropriate imine. The 1H NMR data for the 3-X- and 4-X-PBN's can be correlated with the Hammett equation. For the 3-X series .DELTA..delta. for the .alpha.-proton correlates best with .sigma.+ and has a correlation coeff. of 0.90. For the 4-X series a dual substituent parameter equation using .sigma.R0 gives the best correlation with r = 0.99. The hyperfine splitting consts. of the hydroxyl radical and hydroperoxyl radical adducts of several substituted PBN's are also included and their correlation with the Hammett equation is discussed.

IT **115995-22-7P 130995-65-2P**
RL: PRP (Properties); SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and NMR of)

RN 115995-22-7 CAPLUS
CN 2-Propanamine, N-[(3-methoxyphenyl)methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)



RN 130995-65-2 CAPLUS
CN 2-Propanamine, N-[(2-methoxyphenyl)methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)



IT **40117-28-0P**
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and hyperfine splitting and decay rate for radical adducts and NMR of)
RN 40117-28-0 CAPLUS
CN 2-Propanamine, N-[(4-methoxyphenyl)methylene]-2-methyl-, N-oxide (9CI) (CA INDEX NAME)



L36 ANSWER 11 OF 47 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1995:258379 CAPLUS
DOCUMENT NUMBER: 122:160227
TITLE: Synthesis and separation of the E and Z isomers of simple aldonitrones
AUTHOR(S): Sivasubramanian, Shanmugaperumal; Mohan, Ponnusamy; Thirumalaikumar, Muniappan; Muthusubramanian, Shanmugan
CORPORATE SOURCE: Dep. Org. Chem., Madurai Kamaraj Univ., Madurai, 625 021, India
SOURCE: J. Chem. Soc., Perkin Trans. 1 (1994), (23), 3353-4
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 122:160227
AB The uncommon E isomer of simple aldonitrones has been obtained in significant amts. for the first time in the case of .alpha.-phenyl-N-(.beta.-phenylethyl)nitrones.

=> d hitstr 11

L36 ANSWER 11 OF 47 CAPLUS COPYRIGHT 1999 ACS
IT **161325-26-4P 161325-27-5P**
RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and sepn. of the E and Z isomers of simple aldonitrones and isomerization and)
RN 161325-26-4 CAPLUS
CN Benzeneethanamine, N-[(4-methoxyphenyl)methylene]-, N-oxide, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 161325-27-5 CAPLUS
CN Benzeneethanamine, N-[(4-methoxyphenyl)methylene]-, N-oxide, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



ACCESSION NUMBER: 1995:242557 CAPLUS
DOCUMENT NUMBER: 122:31336
TITLE: Preparation of (S)-.alpha.-phenyl-2-pyridineethanamine (S)-malate and its use as an anticonvulsant and in the **treatment** of **neurodegenerative** disorders
INVENTOR(S): Murray, Robert John; Mathisen, Donald; Balestra, Michel
PATENT ASSIGNEE(S): Fisons PLC, UK; Fisons Corp.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422831	A1	19941013	WO 1994-GB651	19940329
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IL 114388	A1	19990126	IL 1990-114388	19900206
AU 9050927	A1	19910903	AU 1990-50927	19900207
AU 654802	B2	19941124		
NO 9203006	A	19920730	NO 1992-3006	19920730
FI 9203540	A	19920806	FI 1992-3540	19920806
WO 9320052	A1	19931014	WO 1993-GB689	19930401
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9463802	A1	19941024	AU 1994-63802	19940329
AU 682348	B2	19971002		
EP 691957	A1	19960117	EP 1994-911232	19940329
EP 691957	B1	19970813		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08508292	T2	19960903	JP 1994-521814	19940329
JP 3023987	B2	20000321		
NO 9503846	A	19951121	NO 1995-3846	19950928
FI 9504645	A	19951129	FI 1995-4645	19950929

PRIORITY APPLN. INFO.:		
WO 1993-GB689	A	19930401
GB 1993-20273	A	19931001
IL 1990-93286	A0	19900206
WO 1990-GB184	A	19900207
GB 1992-7339	A	19920403
GB 1992-8290	A	19920415
WO 1994-GB651	W	19940329

GI



I

AB (S)-.alpha.-phenyl-2-pyridineethanamine (S)-malate (I), useful in the treatment of **neurodegenerative** disorders and as an anticonvulsant, is prepd. by the pptn. from soln. of a mixt. of .alpha.-phenyl-2-pyridineethanamine or its salts (e.g., the hydrochloride) and (S)-malic acid. Thus, I was prepd. and demonstrated a ED50 of 2.9 mg/kg (p.o.) in the prevention of hind limb tonic extension in rats induced by maximal electroshock.

=>

ACCESSION NUMBER: 1997:413439 CAPLUS
DOCUMENT NUMBER: 127:80093
TITLE: Screening for subclinical **autoimmune** thyroid **diseases** with highly sensitive assays for autoantibodies to thyroglobulin and thyroid peroxidase and serum thyrotropin concentrations
AUTHOR(S): Konno, Norimichi
CORPORATE SOURCE: Konno Endocr. Clin., Sapporo, 060, Japan
SOURCE: Nippon Naibunpi Gakkai Zasshi (1997), 73(3), 451-461
CODEN: NNGZAZ; ISSN: 0029-0661
PUBLISHER: Nippon Naibunpi Gakki
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The prevalence of subclin. autoimmune thyroid diseases (AITD) was investigated with detns. of highly sensitive anti-thyroid peroxidase antibody (TPOAb), anti-thyroglobulin antibody (TgAb) and TSH in serum samples obtained from 2647 ostensibly healthy subjects (1887 males and 760 females, aged 46.0 yr, Mean) residing in Sapporo who were recruited at the hospital for medical examns. The prevalence of thyroid autoantibodies (TAA) was 9.1%, among which 23.6% was TgAb pos. only (>1.83 U/mL), while 46.3% was TPOAb pos. only (>0.34 U/mL), and the remaining 32.2% were both TPOAb and TgAb pos. TAA was pos. in 6.5% for males and 15.8% for females with an age-related increase. The prevalence of subclin. hyperthyroidism (TSH <0.15 mU/L) was 0.79%, of which 42.1% was pos. for TAA. The prevalence of subclin. hypothyroidism (TSH >5.0 mU/L) was 1.1%, of which 20% were TAA pos. The overall prevalence of subclin. autoimmune thyroiditis as defined by TAA pos. eu- and hypothyroidism was 8.8%; 6.3% for males and 15.5% for females. There was a significant inverse correlation between TPOAb and TSH levels (r = -0.21) in subjects with TPOAb pos. only and also a significant correlation between TgAb and TSH levels in subjects with pos. TgAb with or without TPOAb (r = 0.27). This study indicates that the combined anal. of TPOAb, TgAb and TSH may provide more accurate information on the prevalence of AITD in the population study.

ACCESSION NUMBER: 1999:39839 CAPLUS
DOCUMENT NUMBER: 130:217477
TITLE: Immunosuppressive therapy of **lupus** nephritis
AUTHOR(S): Dooley, M. A.; Falk, R. J.
CORPORATE SOURCE: Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
SOURCE: Lupus (1998), 7(9), 630-634
CODEN: LUPUES; ISSN: 0961-2033
PUBLISHER: Stockton Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 50 refs. Aggressive immunosuppressive therapy should be considered for patients with proliferative **lupus** nephritis as the risk for progression to end stage renal disease is high. Intermittent i.v. cyclophosphamide therapy improves renal survival; longer duration of therapy is assocd. with fewer relapse of nephritis and decreased risk of diminished renal function. While azathioprine therapy does not differ statistically from steroids alone in prolonging renal survival, this therapy may be considered in patients with few risk factors for progression to renal insufficiency. Methylprednisolone as a single therapy does not prolong renal survival compared with regimens including cyclophosphamide. Plasmapheresis remains under study but has not shown addnl. benefit in treatment of severe **lupus** nephritis. The potential roles for cyclosporin A and mycophenylate mofetil in the therapy of proliferative **lupus** nephritis remain to be defined. Supportive care including rigorous control of hypertension, consideration of angiotensin receptor inhibition or blockade to reduce proteinuria and prolong renal function, control of hyperlipidemia, **prevention** of osteoporosis, and **prevention** of pregnancy remain important clin. goals. Current research efforts focus on genetic and socioeconomic factors involved in racial differences in expression of **lupus** nephritis, hormonal manipulation to preserve gonadal function during cyclophosphamide therapy, and the potential impact on **lupus** activity of estrogen-contg. oral contraceptives or postmenopausal hormone replacement therapy.

ACCESSION NUMBER: 1999:177924 CAPLUS
DOCUMENT NUMBER: 130:280743
TITLE: Frequent enrichment of CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions.

Towards a reassessment of the physiopathological significance of T cell clonal expansions found in **autoimmune** inflammatory processes

AUTHOR(S): Scotet, Emmanuel; Peyrat, Marie-Alix; Saulquin, Xavier; Retiere, Christelle; Couedel, Christelle; Davodeau, Francois; Dulphy, Nicolas; Toubert, Antoine; Bignon, Jean-Denis; Lim, Anick; Vie, Henri; Hallet, Marie-Martine; Liblau, Roland; Weber, Michel; Berthelot, Jean-Marie; Houssaint, Elisabeth; Bonneville, Marc

CORPORATE SOURCE: Inst. Biologie, Nantes, F-44035, Fr.
SOURCE: Eur. J. Immunol. (1999), 29(3), 973-985
CODEN: EJIMAF; ISSN: 0014-2980
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors recently evidenced a dramatic enrichment for T cells reactive against Epstein-Barr virus (EBV) within inflamed joints of 2 rheumatoid **arthritis** patients. To assess the generality of this phenomenon and its relevance to autoimmunity, the authors studied the responses of CD8 T cells from patients with either acute or chronic inflammatory diseases (rheumatoid **arthritis**, ankylosing spondylitis, psoriatic **arthritis**, Reiter's syndrome, arthrosis, uveitis, multiple sclerosis, encephalitis) against viral proteins derived from EBV and another common herpes virus, human cytomegalovirus (CMV). T cell responses against EBV and/or CMV epitopes were frequently obsd. within CD8 T cells derived from chronic inflammatory lesions, irresp. of their location (knee, eye, brain) and autoimmune features. In most cases, CD8 T cells derived from affected organs yielded stronger antiviral T cell responses than CD8 T cells derived from patients' PBL, even in chronic inflammatory diseases devoid of autoimmune features or induced by defined bacterial agents. These results suggest that the presence of virus-specific T cells within inflamed lesions of patients suffering from **autoimmune diseases** is a general phenomenon assocd. with chronic inflammation rather than the initiating cause of the autoimmune process. Since this phenomenon was sometimes assocd. with long-term T repertoire biases within inflamed lesions, the physiopathol. significance of T cell clonal expansions found in a recurrent fashion within chronically inflamed autoimmune lesions should be interpreted with caution.

ACCESSION NUMBER: 1999:291647 CAPLUS
DOCUMENT NUMBER: 130:291586
TITLE: Rapamycin for **treatment** of cardiac **inflammatory disease**
INVENTOR(S): Armstrong, Jay Joseph
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: Pat. Specif. (Aust.), 13 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 695664	B2	19980820	AU 1996-47983	19960308
AU 9647983	A1	19960919		

PRIORITY APPLN. INFO.: US 1995-401742 19950309

AB A method is provided for treating cardiac **inflammatory disease** in a mammal which comprises administering rapamycin to the mammal orally, parenterally, intravascularly, intranasally, intrabronchially, transdermally, or rectally.

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:46416 CAPLUS
DOCUMENT NUMBER: [redacted]
TITLE: New indications for thalidomide
AUTHOR(S): De Jong-van den Berg, L. T. W.; Rutgers, J.; Cornel, M. C.; Takx-Koehlen, B. C. M. J.
CORPORATE SOURCE: Groningen Inst. Drug Studies, Rijksuniv. Groningen, Groningen, 9713 AW, Neth.
SOURCE: Ziekenhuisfarmacie (1998), 14(4), 190-193
CODEN: ZIFAEM; ISSN: 0169-2720
PUBLISHER: Nederlandse Vereniging van Ziekenhuisapothekers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Dutch
AB A brief review with 38 refs. is given on new indications for thalidomide. Besides the beneficial effects of thalidomide in **erythema nodosum leprosy** the drug is efficacious in other major disorders such as aphthae and ulcers in aids, tuberculosis, autoimmune diseases, and tumors.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1993:579060 CAPLUS
DOCUMENT NUMBER: 119:179060
TITLE: In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosum leprosum
AUTHOR(S): Santos, Dilvani O.; Suffys, Philip N.; Bonifacio, Karla; Marques, Maria A.; Sarno, Euzenir N.
CORPORATE SOURCE: Dep. Cell. Mol. Biol., Fed. Fluminense Univ., Valonguinho, 20400, Brazil
SOURCE: Clin. Immunol. Immunopathol. (1993), 67(3, Pt. 1), 199-203
CODEN: CLIIAT; ISSN: 0090-1229
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The prodn. of tumor necrosis factor (TNF) by Mycobacterium leprae-stimulated phagocyte cells, isolated from lepromatous leprosy patients (LL) and normal individuals, was evaluated, using the highly TNF-sensitive mouse fibrosarcoma cell line WEHI164cl13. Mononuclear cells, isolated from all individuals studied, showed a low level of spontaneous TNF prodn., except for patients undergoing erythema nodosum leprosum (ENL), in which the authors found significantly higher levels of TNF. Addn. of M. leprae to the phagocyte cell culture enhanced TNF prodn.
in all groups studied, except in the group with untreated leprosy patients. Strongest M. leprae-induced TNF release was found in mononuclear cell cultures derived from ENL patients. Patients in the postreactional state showed significantly higher TNF levels than healthy controls. These findings support the idea that TNF plays a key role in the complex symptomatol. of ENL.

ACCESSION NUMBER: 1995:549812 CAPLUS
TITLE: Editorial: adrenal and gonadal **autoimmune diseases**
AUTHOR(S): Smith, Bernard Rees; Furmaniak, Jadwiga
CORPORATE SOURCE: FIRS Lab., RSR Ltd., Cardiff, UK
SOURCE: J. Clin. Endocrinol. Metab. (1995), 80(5), 1502-5
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Unavailable

L14 ANSWER 2 OF 821 CAPLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1999:397013 CAPLUS
TITLE: Effects of systemically applied allopurinol and prednisolone on experimental autoimmune **uveitis**
AUTHOR(S): Augustin, A. J.; Loeffler, K. U.; Sekundo, W.; Grus, F. H.; Lutz, J.
CORPORATE SOURCE: Department of Ophthalmology, University of Bonn, Bonn, D-53105, Germany
SOURCE: Graefe's Arch. Clin. Exp. Ophthalmol. (1999), 237(6), 508-512
CODEN: GACODL; ISSN: 0721-832X
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB To compare the effects of allopurinol to those of prednisolone on the oxidative tissue damage and inflammatory response in exptl. autoimmune **uveitis** (EAU). Expts. were performed using 27 male Lewis rats. EAU was induced by means of crude retina ext., Freund's adjuvant and pertussis toxin. One group of animals served as controls and two groups were treated systemically, one with allopurinol and one with prednisolone.

At the end of the expts. lipid peroxides (LPO), myeloperoxidase activity (MPO), and histol. changes were detd. in the retinal tissue. LPO were measured by two different methods [thiobarbituric acid reactive substances (TBARS) and malondialdehyde-like substances]. Allopurinol led to a significant redn. in LPO and MPO levels. The steroid treatment also resulted in a significant redn. in MPO activity but LPO were significantly reduced only when measured as TBARS. Histol. changes were significantly reduced by allopurinol only. Allopurinol is more effective than prednisolone in treating EAU. Its efficacy can be explained by the antioxidative/antiinflammatory and probably immunol. action. The antiinflammatory effects of prednisolone are not sufficient to reduce the tissue damage. Allopurinol promises to be a useful alternative to steroids in the treatment of **uveitis**.

	Type	Hits	Search Text	DBs
1	BRS	2	"20030078297"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
2	BRS	2	6258852.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
3	BRS	2	6083989.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
4	BRS	131	flitter	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
5	BRS	72742	neuropathic or pain	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
6	BRS	24	flitter and (neuropathic or pain)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
7	BRS	8976	neuropathic or neuroleptic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
8	BRS	31	flitter and (neuropathic or neuroleptic)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
9	BRS	9	(flitter and (neuropathic or neuroleptic)) and nitrone	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
10	BRS	2	5665732.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
11	BRS	61	aryl near nitrone	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
12	BRS	2458	neuropathic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
13	BRS	3	(aryl near nitrone) and neuropathic	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
14	BRS	2	6342523.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
15	BRS	194	514/579.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
16	BRS	485	514/642.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
17	BRS	435	514/643.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
18	BRS	123	514/715.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB

	Time Stamp	Comments	Error Definition	Errors
1	2003/07/21 12:01			0
2	2003/07/18 13:28			0
3	2003/07/18 13:28			0
4	2003/07/18 13:28			0
5	2003/07/18 13:29			0
6	2003/07/18 13:28			0
7	2003/07/18 13:29			0
8	2003/07/18 13:29			0
9	2003/07/18 13:29			0
10	2003/07/21 12:04			0
11	2003/07/21 12:04			0
12	2003/07/21 12:04			0
13	2003/07/21 12:11			0
14	2003/07/21 15:11			0
15	2003/07/21 15:11			0
16	2003/07/21 15:12			0
17	2003/07/21 15:12			0
18	2003/07/21 15:12			0

	Type	Hits	Search Text	DBs
19	BRS	230	514/717.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
20	BRS	116	514/720.ccls.	USPAT; EPO; JPO; DERWENT; IBM_TDB
21	BRS	1	569/50	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
22	BRS	0	569/50.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
23	BRS	1355	514/579.ccls. or 514/642.ccls. or 514/643.ccls. or 514/715.ccls. or 514/717.ccls. or 514/720.ccls.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
24	BRS	4900	(neuropathic adj pain) or neuralgia	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
25	BRS	6	(514/579.ccls. or 514/642.ccls. or 514/643.ccls. or 514/715.ccls. or 514/717.ccls. or 514/720.ccls.) and ((neuropathic adj pain) or neuralgia)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB
26	BRS	2	5455272.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB

	Time Stamp	Comments	Error Definition	Errors
19	2003/07/21 15:12			0
20	2003/07/21 15:12			0
21	2003/07/21 15:12			0
22	2003/07/21 15:12			0
23	2003/07/21 15:13			0
24	2003/07/21 15:13			0
25	2003/07/21 16:29			0
26	2003/07/21 16:29			0